CERo Therapeutics Holdings (CERo Therapeutics Holdings) Total Stockholders Equity : $-34.87 Mil (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Total Stockholders Equity?

CERo Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $-34.87 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. CERo Therapeutics Holdings's Book Value per Share for the quarter that ended in Dec. 2022 was $-3.39. The ratio of a company's debt over equity can be used to measure how leveraged this company is. CERo Therapeutics Holdings's Debt-to-Equity for the quarter that ended in Dec. 2022 was -0.09.

CERo Therapeutics Holdings Total Stockholders Equity Historical Data

The historical data trend for CERo Therapeutics Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Total Stockholders Equity Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Total Stockholders Equity

-23.43

-34.87

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Total Stockholders Equity	-23.43	-34.87

CERo Therapeutics Holdings (NAS:CERO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

CERo Therapeutics Holdings's Book Value per Share for the quarter that ended in Dec. 2022 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-34.871	-	0)	/	10.293
	=	-3.39

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

CERo Therapeutics Holdings's Debt-to-Equity for the quarter that ended in Dec. 2022 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.672	+	2.345)	/	-34.871
	=	-0.09

CERo Therapeutics Holdings Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024